

Receptor Interacting Protein 2 (rip2) in Development of Immune Response

Tech ID: 20537 / UC Case 2001-425-0

INNOVATION

UCLA investigators have determined that Receptor Interacting Protein 2 (RIP2) has novel functions in regulating Th1 helper T cells and the IL-1/IL-18 Toll-like receptor responses of NK cells and presents a target for therapeutic approaches to the treatment of disorders mediated by these cells, including toxic shock and certain autoimmune diseases. Their results suggest that RIP2 plays a pivotal role in Th1 and NK cell-mediated immune responses and that its regulation should provide a therapeutic approach to the treatment of disorders mediated by these cells, such as toxic shock and of certain autoimmune diseases.

PATENT STATUS

| Country | Type | Number | Dated | Case |
|---------------------------|--------------------------------|---------------------------------|------------|----------|
| Patent Cooperation Treaty | Reference for National Filings | WO 03/023393 A1 | 03/20/2003 | 2001-425 |

Patent Pending

CONTACT

UCLA Technology Development Group
 ncd@tdg.ucla.edu
 tel: 310.794.0558.



INVENTORS

► Cheng, Genhong

OTHER INFORMATION

KEYWORDS

therapeutics, research tools

CATEGORIZED AS

- [Research Tools](#)
- [Reagents](#)
- [Screening Assays](#)

RELATED CASES

2001-425-0

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- [Broad Antiviral Therapy with Membrane-Modifying Small Molecules](#)

Gateway to Innovation, Research and Entrepreneurship

UCLA Technology Development Group

10889 Wilshire Blvd., Suite 920, Los Angeles, CA 90095

tdg.ucla.edu

Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu

© 2013 - 2016, The Regents of the University of California

[Terms of use](#)

[Privacy Notice](#)

